Juraschka et al., 2019 - Google Patents
Medulloblastoma in the age of molecular subgroups: a review: JNSPG 75th Anniversary Invited Review ArticleJuraschka et al., 2019
View HTML- Document ID
- 11869418194600155956
- Author
- Juraschka K
- Taylor M
- Publication year
- Publication venue
- Journal of Neurosurgery: Pediatrics
External Links
Snippet
Medulloblastoma is the most common pediatric malignant brain tumor. Advances in molecular profiling have uncovered significant heterogeneity among medulloblastomas and led to the identification of four distinct subgroups (wingless [WNT], sonic hedgehog [SHH] …
- 208000000172 Medulloblastoma 0 title abstract description 87
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Juraschka et al. | Medulloblastoma in the age of molecular subgroups: a review: JNSPG 75th Anniversary Invited Review Article | |
| Ramaswamy et al. | Medulloblastoma: from myth to molecular | |
| Thomas et al. | Medulloblastoma: optimizing care with a multidisciplinary approach | |
| Frühwald et al. | Atypical teratoid/rhabdoid tumors—current concepts, advances in biology, and potential future therapies | |
| Menyhárt et al. | Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas | |
| Qazi et al. | Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma | |
| Chmielik et al. | Heterogeneity of thyroid cancer | |
| Menyhárt et al. | Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches | |
| Abarrategi et al. | Osteosarcoma: cells‐of‐origin, cancer stem cells, and targeted therapies | |
| Richardson et al. | Atypical teratoid rhabdoid tumour: from tumours to therapies | |
| JP2020169212A (en) | Phosphatidylinositol-3-kinase pathway biomarkers | |
| Saleh et al. | The biology of ependymomas and emerging novel therapies | |
| Yadav et al. | The biology and therapeutic implications of tumor dormancy and reactivation | |
| Takeshita et al. | High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer | |
| Schulte et al. | Targeted therapy for neuroblastoma: ALK inhibitors | |
| Mazzola et al. | Role of radiosurgery/stereotactic radiotherapy in oligometastatic disease: brain oligometastases | |
| Ray et al. | Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas | |
| Rozsas et al. | Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma | |
| Decker et al. | Adrenergic blockade promotes maintenance of dormancy in prostate cancer through upregulation of GAS6 | |
| Kim et al. | Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer | |
| Zhang et al. | Thioguanine induces apoptosis in triple-negative breast cancer by regulating PI3K–AKT pathway | |
| Li et al. | The future role of personalized medicine in the treatment of glioblastoma multiforme | |
| Suk et al. | Childhood medulloblastoma: an overview | |
| Cheng et al. | Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects | |
| Wang et al. | Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma |